Skip to content

MDMA for addiction

Studies whose primary subject is both MDMA and Addiction, with an evidence synthesis read across the most-cited and most recent of them.

State of the evidence

Synthesized

Synthesized from 17 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for MDMA, ecstasy, molly, methylenedioxymethamphetamine, Addiction, substance use disorder, then ranked by relevance.

Direct evidence on MDMA for addiction is very limited: one small open-label study in alcohol use disorder found the treatment well tolerated with large self-reported drops in drinking, but it had no control group, so efficacy is unproven. A large randomized controlled trial in comorbid PTSD and alcohol use disorder is only at the protocol stage. Separately, survey, diagnostic, and pharmacovigilance data indicate MDMA itself carries dependence potential, so benefit and risk need careful weighing.

Evidence by study

Direction is which way each study's own result points, not our rating of the study. All 25 matching studies were reviewed; the 17 that directly address the question are shown here.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. 2021 open-label proof-of-concept study 14 Supports MDMA-assisted psychotherapy (two 187.5 mg sessions) was well tolerated with no unexpected adverse events, psychosocial functioning improved, and average alcohol consumption fell from 130.6 to 18.7 units per week nine months after detox, described by the authors as preliminary.
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants. 2019 open-label proof-of-concept study 4 Supports The first four participants tolerated the 8-week MDMA-assisted psychotherapy course with no serious MDMA-related adverse events and no unexpected physiological, blood, or ECG changes; drinking outcomes were not yet reported.
MDMA-assisted PTSD and Alcohol Therapy Trial (MPATHY): study protocol for a double-blind, randomised, controlled outpatient trial of MDMA-assisted integrated exposure-based therapy for comorbid post-traumatic stress disorder and alcohol use disorder 2026 RCT protocol 100 Unclear Describes a planned double-blind trial comparing MDMA-assisted integrated exposure therapy with active-control (niacin)-assisted therapy on PTSD symptoms and heavy drinking days; no outcome data yet.
Why MDMA therapy for alcohol use disorder? And why now? 2018 theoretical paper Supports Argues that MDMA-assisted psychotherapy may suit alcohol use disorder because MDMA lets patients explore painful memories without being overwhelmed, and notes it had not been formally studied for substance use disorders.
Psilocybin and MDMA in Couples Therapy: Investigating Treatment for Substance Use Disorders and Codependency 2025 narrative review Supports Proposes that combining psilocybin-assisted therapy for substance use disorder with MDMA for a partner's codependency in couples therapy may reduce addictive and codependent behaviors.
Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials 2025 umbrella review of meta-analyses of RCTs Mixed Finds strong evidence for psilocybin in depression and MDMA in PTSD, but far fewer meta-analyses for substance use indications (e.g., LSD in alcohol use disorder), and flags methodological limitations and gaps in long-term safety data.
Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey 2020 cross-sectional online survey Supports Reports that naturalistic psychedelic use is associated with self-reported persisting reductions in cannabis, opioid, and stimulant misuse, while noting the design cannot establish causality.
User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study 2010 cross-sectional web survey 600 Supports Users reported benefits including help with addictions and mood disorders, and reported less harm from classic hallucinogens than from MDMA, cannabis, ketamine, and alcohol.
Ecstasy (MDMA) dependence 1999 case series 3 Opposes Describes three cases meeting dependence criteria, arguing MDMA can be addictive in rare cases and that very heavy use may cause lasting neuronal changes; one case was linked to self-medication of PTSD.
Test–re‐test reliability of DSM‐IV adopted criteria for 3,4‐methylenedioxymethamphetamine (MDMA) abuse and dependence: a cross‐national study 2009 test-retest diagnostic study 593 Opposes At baseline 15% met MDMA abuse and 59% met dependence criteria, with moderate test-retest reliability (kappa 0.69) and withdrawal among the most prevalent criteria.
Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users 2014 cross-sectional survey Opposes MDMA users were more likely to report three or more DSM-IV dependence symptoms than users of cocaine, mephedrone, or ketamine, yet less likely to want to use less or seek help.
Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase) 2025 pharmacovigilance database analysis Opposes MDMA reports were associated with significantly greater odds of reported alcohol abuse, substance use disorder, and substance dependence than acetaminophen and oxycodone controls.
Reinforcing Effects of MDMA (‘Ecstasy’) in Drug-Naive and Cocaine-Trained Rats 2001 animal experimental study Opposes Intravenous MDMA was self-administered with equal reinforcing effect in drug-naive and cocaine-trained rats, and MDMA and cocaine produced distinct interoceptive stimuli.
Use and abuse of dissociative and psychedelic drugs in adolescence 2021 review Unclear Notes that little is known about MDMA effects in adolescents and that MDMA produces mixed reinforcing and aversive effects whose balance may differ between adolescents and adults.
Potential Human Neurotoxicity of MDMA (‘Ecstasy’): Subjective Self-Reports, Evidence from an Italian Drug Addiction Centre and Clinical Case Studies 2000 review and clinical case series Opposes Reports that longer-term, larger-dose MDMA consumers were at high risk of psychopathological disturbances including depression, psychotic disorders, and cognitive problems, while noting MDMA was rarely the only drug used.
Neural Correlates of the Severity of Cocaine, Heroin, Alcohol, MDMA and Cannabis Use in Polysubstance Abusers: A Resting-PET Brain Metabolism Study 2012 cross-sectional PET imaging study 49 Opposes Severity of MDMA use correlated negatively with brain metabolism in dorsolateral prefrontal and temporal cortex, controlling for other drugs used.
Methamphetamine and MDMA (Ecstasy) Neurotoxicity: 'of Mice and Men' 2004 review Opposes Argues that rodent and primate evidence indicates MDMA and methamphetamine cause neurotoxicity in dopaminergic and serotonergic neurons, while human data remain limited.

Points of agreement

  • MDMA can meet dependence criteria in a substantial minority of users, and dependence symptoms are reported across survey, diagnostic, and pharmacovigilance data.
  • The only clinical addiction treatment data are small open-label studies in alcohol use disorder reporting tolerability and reduced drinking.
  • Reviewers and trial designers agree MDMA-assisted therapy for substance use disorders is plausible but not yet established by controlled trials.
  • Heavy or long-term MDMA use is linked to psychopathological and brain-metabolism changes, though polydrug use complicates attribution.

Conflicts

  • Open-label alcohol studies suggest benefit, while dependence, self-administration, and adverse-event data suggest MDMA carries its own addiction risk.
  • Some sources describe MDMA as generally non-addictive, whereas diagnostic and survey studies find prevalent dependence symptoms.
  • User surveys report therapeutic benefit for addictions, but these are self-selected retrospective reports that cannot establish causation.

Gaps

  • No completed randomized controlled trial of MDMA for any substance use disorder; the key trial is only a protocol.
  • No controlled efficacy data, blinding integrity data, or long-term durability of drinking outcomes.
  • Small samples (4 and 14) in the alcohol studies and no placebo comparison.
  • Little research in adolescents, on sex differences, or on dose-response for addiction treatment.
  • Unclear how to separate MDMA's therapeutic potential from its dependence liability in the same population.
Browse these studies in the library

Common questions

What does the research agree on about MDMA for addiction?
  • MDMA can meet dependence criteria in a substantial minority of users, and dependence symptoms are reported across survey, diagnostic, and pharmacovigilance data.
  • The only clinical addiction treatment data are small open-label studies in alcohol use disorder reporting tolerability and reduced drinking.
  • Reviewers and trial designers agree MDMA-assisted therapy for substance use disorders is plausible but not yet established by controlled trials.
  • Heavy or long-term MDMA use is linked to psychopathological and brain-metabolism changes, though polydrug use complicates attribution.
Where do studies on MDMA for addiction conflict?
  • Open-label alcohol studies suggest benefit, while dependence, self-administration, and adverse-event data suggest MDMA carries its own addiction risk.
  • Some sources describe MDMA as generally non-addictive, whereas diagnostic and survey studies find prevalent dependence symptoms.
  • User surveys report therapeutic benefit for addictions, but these are self-selected retrospective reports that cannot establish causation.
What is still unknown about MDMA for addiction?
  • No completed randomized controlled trial of MDMA for any substance use disorder; the key trial is only a protocol.
  • No controlled efficacy data, blinding integrity data, or long-term durability of drinking outcomes.
  • Small samples (4 and 14) in the alcohol studies and no placebo comparison.
  • Little research in adolescents, on sex differences, or on dose-response for addiction treatment.
  • Unclear how to separate MDMA's therapeutic potential from its dependence liability in the same population.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is MDMA for addiction, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when MDMA for addiction or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

81 articles · 18 from the last two years · 146,328 participants across 27 studies reporting sample size

Common study designs

review 23 observational cohort 6 cross-sectional study 5 cross-sectional survey 4 theoretical or philosophical paper 4

Research volume by year

Compare topics →

76 studies whose primary subject is MDMA for addiction since 2003

Studies about MDMA for addiction per year, 2003 to 2026, peaking at 9 in 2024 Bar chart: one bar per year, taller where more studies were published that year. 0 5 10 2005 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about MDMA for addiction per year, 2003 to 2026, peaking at 9 in 2024
Year Studies
2003 1
2004 1
2005 1
2006 1
2007 0
2008 1
2009 2
2010 3
2011 0
2012 3
2013 1
2014 2
2015 1
2016 2
2017 4
2018 2
2019 2
2020 5
2021 6
2022 4
2023 7
2024 9
2025 9
2026 9

Research

Synthesize the evidence →

MDMA-Assisted Therapy for Veterans with Comorbid Posttraumatic Stress Disorder and Alcohol Use Disorder: Clinical Outcomes from the First Open-Label Pilot Trial.

Alcohol October 30, 2026 Erica Eaton, Christy Capone, Brian J Gully et al.

Co-occurring posttraumatic stress disorder and alcohol use disorder (PTSD-AUD) are highly prevalent among U.S. Veterans and associated with greater symptom severity, functional impairment, and poorer outcomes than either disorder alone. Existing treatments demonstrate modest effectiveness, with persistent challenges in engagement, retention, and sustained improvement. To evaluate the...

DOI: 10.1016/j.alcohol.2026.107464 (opens in new tab) Full text (opens in new tab) Alcohol use disorder Comorbidity MDMA-Assisted Therapy Posttraumatic stress disorder +1

Mechanisms of vesicular monoamine transporter 2 modulation by amphetamines and lobeline.

Cell Reports October 26, 2026 Di Wu, Chuanyu Liu, Hongshuang Wang et al.

Amphetamine-type stimulants (ATSs) disrupt the brain monoaminergic system and strongly stimulate motivation, movement, and addiction. Vesicular monoamine transporter 2 (VMAT2) plays a vital role in monoaminergic neurotransmission by sequestering monoamines in presynaptic vesicles. How ATS binds to and regulates VMAT2 remains elusive. Here, we report the cryo-EM structures of human VMAT2 in...

DOI: 10.1016/j.celrep.2026.118205 (opens in new tab) Full text (opens in new tab) MDMA Addiction Cp Dat +4

MDMA-assisted PTSD and Alcohol Therapy Trial (MPATHY): study protocol for a double-blind, randomised, controlled outpatient trial of MDMA-assisted integrated exposure-based therapy for comorbid post-traumatic stress disorder and alcohol use disorder

BMJ Open July 1, 2026 Kirsten Morley, Shalini Arunogiri, Katherine L. Mills et al.

INTRODUCTION: The treatment of comorbid post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) is significantly more challenging than the treatment of either disorder alone. While gold standard evidence-based treatments exist for this comorbidity, clinically significant improvements are only observed in approximately half of clinical trial participants. The use of adjunctive...

DOI: 10.1136/bmjopen-2025-114896 (opens in new tab) Full text (opens in new tab) Alcohol use disorder Major depressive disorder Dosing Randomized controlled trial +11

Happy water overdose: A trending but fatal street drug

Myanmar Medical Journal June 4, 2026 Aung Kyaw Thu, Zaw Hlaing Toe, Si Thu Linn

“Happy water” has been gaining popularity among party goers. The effect of consuming this drug can be fatal. Two patients of “Happy water” overdose were admitted for reduced level of consciousness after enjoying a farewell party at nightclub. Urine for toxicology screening was found to be positive for methylenedioxymethamphetamine (MDMA), methamphetamine, diazepam and tramadol. “Happy water” is...

DOI: 10.64455/xmma0028 (opens in new tab) MDMA Addiction Mephedrone Stimulant +13

Synthetic Drugs and Behavioural Addictions: LSD, MDMA and Digital Toxicity

June 1, 2026 Sharda More-Pol

The emergence of contemporary psychological stressors, synthetic psychoactive substance abuse, and non-substance behavioral dependency networks presents critical investigative challenges within public healthcare and classical toxicology (Agadatantra), traditionally analyzed through the concepts of Madya (intoxicants), Mada (intoxication), and severe cognitive perversion (Prajñāparādha). This...

DOI: 10.63247/ayurveda360.cfa.agadatantra.c011 (opens in new tab) Lysergic acid diethylamide MDMA Cognition Parallels +5

The Ecstasy of Gold in Neurodiversity: Focus on the Use of Psychedelics in Autism Spectrum Disorder

Preprints.org April 29, 2026 Stefano Marini, Domenico de Berardis preprint

Psychedelic drugs are serotonergic hallucinogens that can be divided into two types: naturally occurring (psilocybin, psilocin, and N,N-dimethyltryptamine) and synthetic (LSD, MDMA, 2,5-dimethoxy-4-iodoamphetamine, and ketamine). Psychedelics generally work on 5-hydroxytryptamine receptors and might be useful in cognitive enhancement, brain connectivity, neuroplasticity, and neuronal...

DOI: 10.20944/preprints202604.1998.v1 (opens in new tab) Addiction Autism spectrum disorder Hallucinogen Psychopathology +4

New psychoactive substances (designer drugs): an approach to classification

Neurology Bulletin March 23, 2026 Azat R. Asadullin, Elvina A. Akhmetova, Ilia S. Efremov et al.

BACKGROUND: Substance use disorders remain a global public health problem. In recent decades, the drug market has undergone substantial changes, with traditional drugs increasingly replaced by new psychoactive substances characterized by high toxicity and strong addictive potential. Their distribution via the Internet and social media impedes control and increases risks to public health. AIM:...

DOI: 10.17816/nb689708 (opens in new tab) Addiction Lysergic acid diethylamide MDMA Psilocybin +10

Partydrogen im Überblick

Psychopharmakotherapie 2026 Antonia Bendau, Felix Betzler, Twyla Michnevich et al. 1 citation

Party drugs encompass a broad spectrum of legal and illegal psychoactive substances used in party settings such as clubs, festivals, raves or private gatherings to modulate mood, perception, social interaction and bodily states. Most commonly, alcohol and cannabis are consumed, followed by amphetamine, MDMA (“ecstasy”), cocaine and ketamine. Synthetic cathinones, GHB/GBL (“liquid ecstasy”),...

DOI: 10.52778/ppt20260001 (opens in new tab) Serotonergic MDMA Addiction Cannabis +16

Possible Effects of MDMA on Vehicle Driving Competencies

Transportation research procedia 2026 Samuel Hubočan, Matúš Madleňák

Safety and security in traffic is a fundamental need of every road user. There are many factors that have a direct impact on this need. It can be assumed that vehicle driving competencies represent one of these factors. A vehicle driver should be vigilant, decisive and capable of practical use of traffic rules implied by the legal system. Addictive substances can disrupt driver’s capabilities...

DOI: 10.1016/j.trpro.2025.12.042 (opens in new tab) MDMA Addiction Poison control Orientation vector space +3

Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials

Journal of Clinical Medicine December 29, 2025 Monika Dominiak, Adam Gędek, Szymon Modrzejewski et al. 2 citations

Background: Psychedelic-assisted therapy is gaining renewed attention as a potential treatment for various mental disorders. Despite increasing numbers of randomized controlled trials (RCTs) and meta-analyses, a comprehensive synthesis of the evidence across different substances and indications is lacking. This umbrella review aims to evaluate the effectiveness and safety of...

DOI: 10.3390/jcm15010253 (opens in new tab) MDMA Psilocybin Major depressive disorder Alcohol use disorder +8

Clinical trials

All mdma for addiction trials →